Results 1 to 10 of about 1,266 (177)

Striving for optimal bronchodilation: focus on olodaterol

International Journal of COPD, 2016
Cristoforo Incorvaia,1 Marcello Montagni,2 Elena Makri,1 Gian Galeazzo Riario-Sforza,1 Erminia Ridolo21Allergy/Pulmonary Rehabilitation, Istituti Clinici di Perfezionamento Hospital, Milan, Italy; 2Department of Clinical and Experimental Medicine ...
Incorvaia C, Montagni M, Makri E, Riario-Sforza GG, Ridolo E   +4 more
doaj   +8 more sources

Olodaterol exerts anti-inflammatory effects on COPD airway epithelial cells [PDF]

Respiratory Research, 2021
Background Airway inflammation is a key feature of chronic obstructive pulmonary disease (COPD) and inhaled corticosteroids (ICS) remain the main treatment for airway inflammation.
Nan Yang, Gurpreet K. Singhera, Yi Xuan Yan, Michael P. Pieper, Janice M. Leung, Don D. Sin, Delbert R. Dorscheid   +6 more
doaj   +4 more sources

A Comparison of the Molecular Pharmacological Properties of Current Short, Long, and Ultra-Long-Acting β₂-Agonists Used for Asthma and COPD. [PDF]

Pharmacol Res Perspect
ABSTRACT β‐agonists have been used in asthma for 120 years. There are two recent changes: ultra‐long‐acting agonists for COPD and new asthma guidelines recommending formoterol/ICS inhalers phasing out short‐acting salbutamol inhalers. Few studies directly compare the molecular pharmacological properties of short (salbutamol, terbutaline, fenoterol ...
Proudman RGW, Baker JG.
europepmc   +2 more sources

Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease [PDF]

Therapeutic Advances in Respiratory Disease, 2018
Background: The TORRACTO ® study evaluated the effects of tiotropium/olodaterol versus placebo on endurance time during constant work-rate cycling and constant speed shuttle walking in patients with chronic obstructive pulmonary disease (COPD) after 12 ...
François Maltais, Denis O’Donnell, Juan Bautista Gáldiz Iturri, Anne-Marie Kirsten, Dave Singh, Alan Hamilton, Kay Tetzlaff, Yihua Zhao, Richard Casaburi   +8 more
doaj   +2 more sources

Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studies

International Journal of COPD, 2014
Andrea Koch,1 Emilio Pizzichini,2 Alan Hamilton,3 Lorna Hart,3 Lawrence Korducki,4 Maria Cristina De Salvo,5 Pierluigi Paggiaro6 1Medical Clinic III for Pneumology, Allergology, Sleep and Respiratory Medicine, University Hospital Bochum-Bergmannsheil ...
Koch A, Pizzichini E, Hamilton A, Hart L, Korducki L, De Salvo MC, Paggiaro P   +6 more
doaj   +2 more sources

Cost-Effectiveness Analysis of Fixed-Dose Tiotropium/Olodaterol versus Tiotropium for COPD Patients in China [PDF]

International Journal of COPD, 2023
Ying Lan,1 Nan Yang,2 Yirong Wang,1 Yan Yang,1 Min Xu,1 Qin He1 1Department of Pharmacy, Affiliated Hospital of Southwest Jiaotong University, the Third People’s Hospital of Chengdu, Chengdu, Sichuan, 610031, People’s Republic of China; 2West China ...
Lan Y, Yang N, Wang Y, Yang Y, Xu M, He Q   +5 more
doaj   +2 more sources

Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study

International Journal of COPD, 2016
Rüdiger Sauer,1 Michaela Hänsel,2 Roland Buhl,3 Roman A Rubin,4 Marcel Frey,5 Thomas Glaab2,3 1Lung Centre Ulm, Ulm, Germany; 2Boehringer Ingelheim Pharma GmbH & Co.
Sauer R, Hänsel M, Buhl R, Rubin RA, Frey M, Glaab T   +5 more
doaj   +1 more source

Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2–4 COPD: results from two replicate 48-week studies

International Journal of COPD, 2014
Gary T Ferguson,1 Gregory J Feldman,2 Peter Hofbauer,3 Alan Hamilton,4 Lisa Allen,5 Lawrence Korducki,5 Paul Sachs6 1Pulmonary Research Institute of Southeast Michigan, Livonia, MI, 2S Carolina Pharmaceutical Research, Spartanburg, SC, USA; 3Pneumologie,
Ferguson GT, Feldman GJ, Hofbauer P, Hamilton A, Allen L, Korducki L, Sachs P   +6 more
doaj   +1 more source

Assessment of drug permeability using a small airway microphysiological system [PDF]

Frontiers in Pharmacology
BackgroundThere is a need to reliably predict the permeability of inhaled compounds during the development of new and generic drugs. A small airway microphysiological system (MPS) that can recapitulate the pulmonary air-liquid interface (ALI) with ...
Robert M. Geiger, Shekh M. Rahman, Md Shadiqur Rashid Roni, Catherine Sullenberger, Sabyasachy Mistry, Katherine Shea, Isra Tariq, Omnia A. Ismaiel, Murali K. Matta, Paula L. Hyland, Sasha Berdichevski, Sasha Berdichevski, Alexandre J. S. Ribeiro, Ksenia Blinova, Wenlei Jiang, Ross L. Walenga, Bryan Newman, Donna A. Volpe, Kevin A. Ford   +18 more
doaj   +2 more sources

Differential pharmacology and clinical utility of long-acting bronchodilators in COPD – focus on olodaterol

Therapeutics and Clinical Risk Management, 2015
Maria Gabriella Matera,1 Josuel Ora,2 Mario Cazzola2,3 1Department of Experimental Medicine, Unit of Pharmacology, Second University of Naples, Naples, 2Division of Respiratory Medicine, University Hospital Tor Vergata, 3Department of Systems Medicine ...
Matera MG, Ora J, Cazzola M
doaj   +1 more source